| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Apr'15 | Apr'14 | Apr'13 | Apr'12 | Apr'11 |
|---|---|---|---|---|---|---|---|---|
CASH FLOWS FROM OPERATING ACTIVITIES | ||||||||
Net loss | ||||||||
-8,394 | -14,144 | -8,839 | -43,923 | -14,081 | -19,541 | -9,415 | -15,712 | 10,448 |
Adjustments to reconcile net loss to net cash used in operating activities | ||||||||
Depreciation and amortization | ||||||||
5 | 9 | 13 | 18 | 148 | 150 | 148 | 206 | 311 |
Amortization of right of use asset | ||||||||
102 | 0 | - | - | - | - | - | - | - |
Amortization of deferred compensation | ||||||||
- | - | - | - | - | - | - | 0 | 0 |
Interest on debt instruments | ||||||||
- | - | - | - | 45 | 2,181 | 4,236 | 7,397 | 171 |
Loss on debt settlement and extinguishment | ||||||||
- | - | - | - | - | - | - | 0 | 0 |
Loss on impairment, disposal and write down of long-lived assets | ||||||||
- | - | - | 33,265 | 1,034 | 0 | 0 | 123 | 302 |
Loss (gain) on disposal of property and equipment | ||||||||
-0 | 0 | -0 | 74 | 6 | -2 | -35 | - | - |
Issuance and vesting of compensatory stock options and warrants | ||||||||
171 | 316 | 498 | 529 | 769 | 8,042 | 84 | 65 | 127 |
Issuance of common stock below market value | ||||||||
- | - | - | - | - | - | - | 0 | 0 |
Issuance of common stock as compensation | ||||||||
0 | 190 | 79 | 1 | 117 | 651 | 185 | 127 | 59 |
Issuance of common stock for services rendered | ||||||||
100 | 100 | 0 | - | - | - | - | 0 | 0 |
Deemed dividend on preferred stock | ||||||||
0 | 7,330 | 0 | - | - | - | - | - | - |
Issuance of note payable for services rendered | ||||||||
- | - | - | - | - | - | - | 0 | 0 |
Contributions of capital through services rendered by stockholders | ||||||||
- | - | - | - | - | - | - | 0 | 0 |
Change in the fair value of warrants | ||||||||
- | - | 192 | 298 | 382 | -721 | 0 | - | - |
Amortization of premium on marketable securities | ||||||||
-1 | 91 | 187 | 652 | 674 | 0 | 0 | - | - |
Deferred income taxes | ||||||||
- | - | - | -7,962 | 0 | 0 | - | - | - |
Changes in operating assets and liabilities | ||||||||
Accounts receivable, prepaid expenses and other assets | ||||||||
322 | 122 | -1,110 | -23 | 793 | -519 | 245 | -74 | 38 |
Inventory | ||||||||
- | - | - | - | 0 | -99 | 20 | -7 | 238 |
Accounts payable and accrued liabilities | ||||||||
883 | 729 | -4,997 | 1,895 | 2,724 | -2,089 | 70 | -404 | 796 |
Long term portion of lease liability | ||||||||
-99 | 0 | - | - | - | - | - | - | - |
Net cash used in operating activities | ||||||||
-7,556 | -5,499 | -12,140 | -15,871 | -9,748 | -9,261 | -4,921 | -8,278 | -8,403 |
CASH FLOWS FROM INVESTING ACTIVITIES | ||||||||
Purchase of marketable securities | ||||||||
618 | 493 | 299 | 7,255 | 55,142 | 0 | 0 | - | - |
Sale of marketable securities | ||||||||
-620 | -7,856 | -4,053 | -29,390 | -14,319 | 0 | 0 | - | - |
Purchase of property and equipment | ||||||||
3 | 7 | 4 | 2 | 4 | 9 | 17 | 17 | 240 |
Proceeds from the sale of property and equipment | ||||||||
- | - | - | 75 | 6 | 0 | 4 | 4 | 0 |
Capitalization of patent costs and license rights | ||||||||
- | - | - | - | 105 | 137 | 134 | 247 | 223 |
Net cash provided by investing activities | ||||||||
-1 | 7,354 | 3,749 | 22,206 | -40,925 | -147 | -147 | -261 | -463 |
CASH FLOWS FROM FINANCING ACTIVITIES | ||||||||
Proceeds for issuance of common stock and pre-funded warrants, net of issuance costs | ||||||||
- | - | - | - | 543 | 62,044 | 0 | 8,733 | 4,901 |
Proceeds from the exercise of warrants | ||||||||
96 | 0 | - | - | - | - | - | - | - |
Repurchase of outstanding warrants | ||||||||
- | - | - | - | - | - | 380 | 0 | 0 |
Proceeds from stockholder notes payable | ||||||||
- | - | - | - | - | - | - | 0 | 0 |
Proceeds from issuance of notes payable, net of issuance costs | ||||||||
- | - | - | - | 172 | 141 | 102 | 837 | 4,389 |
Proceeds from convertible notes, net of issuance costs | ||||||||
- | - | - | - | - | - | - | 4,514 | 0 |
Proceeds for issuance of convertible preferred stock, net of issuance costs | ||||||||
0 | 8,907 | 0 | - | - | - | 4,351 | 3,500 | 0 |
Payments on notes - short-term | ||||||||
- | - | - | - | 435 | 135 | 100 | 118 | 104 |
Payments on notes - long-term | ||||||||
- | - | - | - | - | - | - | 8,000 | 0 |
Net cash provided by financing activities | ||||||||
96 | 8,907 | 0 | - | 280 | 66,945 | 3,972 | 9,467 | 9,186 |
Net change in cash and cash equivalents | ||||||||
-7,461 | 10,762 | -8,391 | 6,335 | -50,394 | 57,537 | -1,096 | 927 | 319 |
Non-cash financing activity | ||||||||
Adoption of ASU 2017-11: Reclassification of equity related financial instruments | ||||||||
0 | 33 | - | - | - | - | - | - | - |
Interest | ||||||||
- | - | - | - | 3 | 30 | 2 | 14 | 3 |
Income taxes | ||||||||
- | - | - | - | - | - | - | 0 | 0 |
Restricted stock issued during period in payment of interest on convertible notes | ||||||||
- | - | - | - | 11 | 220 | 745 | - | - |
Common stock issued for payment of dividends on Series C Convertible Preferred stock | ||||||||
- | - | - | - | - | 1,300 | - | - | - |
Series D Convertible Preferred Stock issued as consideration for cancellation of $4.6 million in outstanding principal amount of a convertible promissory note issued by the Company on July 1, 2011 | ||||||||
- | - | - | - | - | 4,600 | - | - | - |
Common stock issued as payment for dividends on the Series D Convertible Preferred stock | ||||||||
- | - | - | - | - | 1,104 | - | - | - |
Goodwill recorded for Phyxius Pharma asset purchase for which common stock and preferred stock were issued | ||||||||
- | - | - | - | - | 11,265 | - | - | - |